Company Overview
Ajooni Biotech Limited manufactures and sells cattle feed in India. Its portfolio includes cattle feed chips, camel and pig feed, cotton oil cakes, mustard oil cakes, and feed supplements. The company was incorporated in 2010 and is based in Mohali, India.
Why Investors Should Care
Net profit has compounded at 56.6% per year over the last five years.
Revenue has grown at a 34.8% CAGR over the past five years.
Trades at a P/E of 11.8, below the sector median of 19.6.
Carries low leverage with a debt-to-equity ratio of 0.29.
Recent Developments
- Mar 2026 Revenue of ₹182.38 Cr (+59.0% YoY); net profit ₹4.32 Cr.
- Trailing 12 Months Year-on-year growth — revenue +99.8%, earnings +28.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 34.8%, profit CAGR 56.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 34.78% |
| 1 Year: | 99.80% |
Compounded Profit Growth
| 5 Years: | 56.63% |
| 1 Year: | 28.16% |
Stock Price Performance
| 1 Year: | -43.24% |
| 6 Months: | -30.99% |
| 3 Months: | -25.57% |
| 1 Month: | -7.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.23 · Neutral
P/E of 11.76 is below the sector median of 19.65 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 34.8% over 5 years.
- Profit CAGR of 56.6% over 5 years.
CONS
- Trading 49.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AJOONI Ajooni Biotech Limited NSE | 2.94 | 11.76 | ₹50.64 Cr | 0.00% | 6.97% | 4.40% | 34.78% | 56.63% |
| 2 | HINDUNILVR Hindustan Unilever Limited NIFTY50NSE | 1,828.30 | 40.72 | ₹4.30 L Cr | 2.36% | 22.15% | 30.86% | 2.31% | 14.12% |
| 3 | ITC ITC Limited NIFTY50NSE | 258.90 | 15.67 | ₹3.24 L Cr | 6.27% | 36.47% | 28.53% | 3.65% | 2.54% |
| 4 | NESTLEIND Nestlé India Limited NIFTY50NSE | 1,189.90 | 60.19 | ₹2.29 L Cr | 0.91% | 62.44% | 79.99% | 17.01% | 23.05% |
| 5 | DMART Avenue Supermarts Limited NSE | 3,166.00 | 67.49 | ₹2.07 L Cr | 0.00% | 16.41% | 12.14% | 17.14% | 7.69% |
| 6 | VBL Varun Beverages Limited NSE | 400.80 | 40.08 | ₹1.36 L Cr | 0.46% | 19.44% | 16.85% | 17.26% | 26.57% |
| 7 | BRITANNIA Britannia Industries Limited NSE | 4,625.00 | 42.78 | ₹1.11 L Cr | 1.89% | 61.21% | 49.61% | 5.66% | 2.95% |
| 8 | MARICO Marico Limited NIFTY_MIDNSE | 775.00 | 53.23 | ₹1.01 L Cr | 0.51% | 38.75% | 41.85% | 11.82% | 10.61% |
| 9 | TATACONSUM Tata Consumer Products Limited NIFTY50NSE | 959.80 | 58.10 | ₹94,990.45 Cr | 1.05% | 8.29% | 7.08% | 13.87% | 8.61% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|
| Revenue | 25.72 Cr | 34.03 Cr | 29.27 Cr |
| Cost of Revenue | 22.57 Cr | 29.00 Cr | 22.70 Cr |
| Gross Profit | 3.16 Cr | 5.04 Cr | 6.57 Cr |
| Operating Expenses | 2.61 Cr | 4.34 Cr | 5.63 Cr |
| Operating Income | 54.41 L | 69.18 L | 94.11 L |
| EBITDA | 1.08 Cr | 1.32 Cr | 2.31 Cr |
| Interest Expense | 5.90 L | 6.83 L | 2.15 L |
| Pretax Income | 79.47 L | 1.01 Cr | 1.91 Cr |
| Tax Provision | 17.96 L | 27.96 L | 36.80 L |
| Net Income | 61.51 L | 73.20 L | 1.54 Cr |
| Diluted EPS | 0.04 | 0.04 | - |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 74.49 Cr | 80.11 Cr | 114.69 Cr | 182.38 Cr |
| Cost of Revenue | - | 65.74 Cr | 70.35 Cr | 97.03 Cr | 147.93 Cr |
| Gross Profit | - | 8.74 Cr | 9.76 Cr | 17.66 Cr | 34.45 Cr |
| Operating Expenses | - | 6.98 Cr | 8.25 Cr | 14.76 Cr | 30.28 Cr |
| Operating Income | - | 1.76 Cr | 1.51 Cr | 2.90 Cr | 4.17 Cr |
| EBITDA | - | 3.05 Cr | 4.42 Cr | 5.72 Cr | 8.65 Cr |
| Interest Expense | - | 46.86 L | 54.87 L | 29.90 L | 70.97 L |
| Pretax Income | - | 1.58 Cr | 3.00 Cr | 4.33 Cr | 5.74 Cr |
| Tax Provision | - | 45.22 L | 83.49 L | 95.72 L | 1.42 Cr |
| Net Income | - | 1.12 Cr | 2.16 Cr | 3.37 Cr | 4.32 Cr |
| Diluted EPS | 0.16 | 1.51 | 0.22 | 0.20 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 58.73 Cr | 47.52 Cr | 95.05 Cr | 120.37 Cr |
| Current Assets | - | 34.67 Cr | 32.33 Cr | 62.00 Cr | 74.48 Cr |
| Cash & Equivalents | - | 30.93 L | 42.82 L | 6.83 Cr | 41.90 L |
| Inventory | - | 6.99 Cr | 15.37 Cr | 23.99 Cr | 39.46 Cr |
| Receivables | - | 20.55 Cr | 12.96 Cr | 16.22 Cr | 17.83 Cr |
| Total Liabilities | - | 17.06 Cr | 4.81 Cr | 6.97 Cr | 29.17 Cr |
| Current Liabilities | - | 15.21 Cr | 3.01 Cr | 5.48 Cr | 27.86 Cr |
| Long Term Debt | - | 1.75 Cr | 1.68 Cr | 1.28 Cr | 1.02 Cr |
| Total Debt | - | 5.18 Cr | 2.17 Cr | 1.94 Cr | 17.76 Cr |
| Total Equity | - | 41.67 Cr | 42.71 Cr | 88.08 Cr | 91.19 Cr |
| Shares Outstanding | - | 9.94 Cr | 9.94 Cr | 17.22 Cr | 17.22 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -5.58 Cr | 22.91 Cr | -31.97 Cr | -5.73 Cr |
| Investing Cash Flow | - | -15.82 Cr | 7.64 Cr | -17.13 Cr | -15.77 Cr |
| Financing Cash Flow | - | 21.66 Cr | -3.57 Cr | 24.83 Cr | 15.09 Cr |
| Capital Expenditure | - | -2.86 Cr | -5.60 Cr | -2.03 Cr | -18.03 Cr |
| Free Cash Flow | - | -8.44 Cr | 17.31 Cr | -34.01 Cr | -23.76 Cr |
| Net Change in Cash | - | 25.20 L | 26.98 Cr | -24.28 Cr | -6.41 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 11.7% | 12.2% | 15.4% | 18.9% |
| Operating Margin % | - | 2.4% | 1.9% | 2.5% | 2.3% |
| Net Margin % | - | 1.5% | 2.7% | 2.9% | 2.4% |
| ROE % | - | 2.7% | 5.1% | 3.8% | 4.7% |
| ROCE % | - | 4.1% | 3.4% | 3.2% | 4.5% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AJOONI
Ajooni Biotech Ltd. Key Financial Ratios – Valuation, Profitability & More - Value Research
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQdnpRN1ZnZ0RPd0haMUFRNHFpZUJlUjl2bUFobmZQaHIwY1RhclBZdlk1djEyaU5sVzdQemRIVFZCOUZjUkthTUhiTU9qM2ZrTWl0emRIVnpfWDRmNFJOWmV6dWU2TGowZkVEdzZqSjBzcGEyazc1VjBEM0dKTTFqYzVjdjhQX2c?oc=5" …
Ajooni Biotech FY26 net profit rises 28% on revenue surge - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPMHR2cGZyTjlqZmpmcE96UnlNR0Q5bTE0WlE4bFpJay1zM2Q2NExpTVgya290XzFmNklMc1FiSEFlYnM5bGFWdnpIZWYwTHExeDFiV3B2a3JER2M4OGZCZUlXTnU2eVhrV1p3dC1JM1ZxX0JyT2lZdG8yWG13bnB2cFQtQXF2dm9MZVBuVC…
Ajooni Biotech NSE:AJOONI SEBI Website Compliance Update - Kalkine India
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNWnBJOHRpeVVIM0lELVdYb0JfdVpLcklRM1k5bHFuMFJRc0RxU29CMU1MNDB2SEppaGk0a1otNjcyZlhQMGhJcjRTZzY0d0RPZVcyNjQ1Q3VWYlZzb3JEQmgwUkZuSjYyWTBjRXYwYkpwdmVkbVdZdjdwZWEya2p0TDYyTU5KZmRRRHBtQj…
Ajooni Biotech (NSE:AJOONI) Has Some Way To Go To Become A Multi-Bagger - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPc0N5WVBjTVpBdzNxR0NZaDdDSTF5UFg0VUM3WW9OU29XdndPdmI2MDVzT2xFUkRvZ0QyS2JrNkFtb3RUT0hSbmpnYS15MWU0cGwzOFQ1dHRBLUd1X0hiQ3g1Rl9Kc1JvbzFvNzhXY0dMM00xZ21RV2N3d0VXdVpUaFRrY2dieTBTNENqaW…
Ajooni Biotech Share Price: Buy or Sell - Univest
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9WMEVOSG1ORjJjM1FQd0VadEw1X0xWZVp2REZ4T00xRWFGV0dDYmlzQ3RsNnp2S01Vd1BFX3pLbV9FVGV3WndHQkRfS3VwUTl1T2c4MV9lZzkyMVowNDNuamlrMG1MOVJ1em9HUE5GMEZKemlrZFlr?oc=5" target="_blank">Ajooni …
Ajooni Biotech Ltd - Equitypandit
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE5FWS1PSFlPT0I2UkdneU5pYWZnVzNrbjlEeXB5LVgzLUhvRXhCaDM3TTdteTJaYzdibGhZOE5yem1BR0FoZ1pheUF6NHdBSXhHNklMZ19FZHRGTTNhdkdabw?oc=5" target="_blank">Ajooni Biotech Ltd</a> <fo…
AJOONI — Frequently Asked Questions
What is the current share price of Ajooni Biotech Limited (AJOONI)?
As of 2026-10-24 04:55 IST, Ajooni Biotech Limited (AJOONI) trades at ₹2.94 on NSE. Its 52-week range is ₹2.87 to ₹5.85.
What is the market capitalisation of AJOONI?
Ajooni Biotech Limited (AJOONI) has a market capitalisation of ₹50.64 Cr on NSE.
What is the P/E ratio of AJOONI?
AJOONI trades at a trailing price-to-earnings (P/E) ratio of 11.76. The industry average P/E is 19.65. Its price-to-book (P/B) ratio is 0.57.
What is the return on equity (ROE) of AJOONI?
AJOONI has a return on equity (ROE) of 4.40%. Its return on capital employed (ROCE) is 6.97%.
Is AJOONI a good stock to buy?
This page provides a data-driven analysis of Ajooni Biotech Limited (AJOONI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.